Theravance Biopharma, Inc. (TBPH) earnings
Quarterly results of Theravance Biopharma, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Theravance Biopharma, Inc. was expected to report around November 9, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Theravance Biopharma, Inc. reported revenue of $20.7M (-20.9% on the same quarter a year earlier) and a net loss of $5.9M.
Diluted earnings per share were -$0.11.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $20.7M | -20.9% | -$5.9M | -$0.11 |
| Q1 FY2026 | $17.7M | +15% | -$4.9M | -$0.10 |
| Q4 FY2025 | $45.9M | +144.7% | $61M | $1.15 |
| Q3 FY2025 | $20M | +18.5% | $3.6M | $0.07 |
| Q2 FY2025 | $26.2M | - | $54.8M | $1.08 |
| Q1 FY2025 | $15.4M | - | -$13.6M | -$0.27 |
| Q4 FY2024 | $18.8M | - | -$15.5M | -$0.31 |
| Q3 FY2024 | $16.9M | - | -$12.7M | -$0.26 |
When is Theravance Biopharma, Inc.'s next earnings date?
Theravance Biopharma, Inc. was expected to report around November 9, 2026; nothing is on file with the SEC yet.
What were Theravance Biopharma, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Theravance Biopharma, Inc. reported revenue of $20.7M and a net loss of $5.9M. The figures come from its filing with the SEC.
Is Theravance Biopharma, Inc.'s revenue growing?
Revenue in Q2 FY2026 was $20.7M, down 20.9% from $26.2M in the same quarter a year earlier.
Get an email when TBPH reports
Follow TBPH and we email you its next results the day they are filed, with the numbers explained.